We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

144 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 62 increasing their positions, 30 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 30

55% more call options, than puts

Call options by funds: $266K | Put options by funds: $172K

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0.75% less ownership

Funds ownership: 68.85% → 68.1% (-0.75%)

1% less funds holding

Funds holding: 146 → 144 (-2)

21% less capital invested

Capital invested by funds: $1.21B → $953M (-$257M)

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

Holders
144
Holders Change
-2
Holders Change %
-1.37%
% of All Funds
2.31%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.1%
New
20
Increased
62
Reduced
30
Closed
19
Calls
$266K
Puts
$172K
Net Calls
+$94K
Net Calls Change
-$553K

Top Buyers

Rank Fund Capital Flow
1
KA
Kinnevik AB
Sweden
+$75M
2
State Street
State Street
Massachusetts
+$32.5M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$31.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$16.4M
5
BlackRock
BlackRock
New York
+$8.83M

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$27.9M
2
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$10.1M
3
AIM
ARK Investment Management
Florida
-$2.55M
4
Lazard Asset Management
Lazard Asset Management
New York
-$1.38M
5
GCM
Graham Capital Management
Connecticut
-$1.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$5.36M +$4.47M +455,977 +190%
Rafferty Asset Management
27
Rafferty Asset Management
New York
$4.6M +$4.15M +423,541 +245%
Goldman Sachs
28
Goldman Sachs
New York
$4.49M +$2.21M +224,936 +63%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$3.9M +$14.8K +1,506 +0.3%
Sumitomo Mitsui Trust Group
30
Sumitomo Mitsui Trust Group
Japan
$3.5M -$355K -36,218 -7%
NAMA
31
Nikko Asset Management Americas
New York
$3.5M -$355K -36,218 -7%
Bank of America
32
Bank of America
North Carolina
$3.25M +$2.19M +222,998 +112%
PCM
33
Pentwater Capital Management
Florida
$3.08M +$981K +100,000 +33%
AllianceBernstein
34
AllianceBernstein
Tennessee
$3.01M -$27.9M -2,846,739 -88%
Mitsubishi UFJ Trust & Banking
35
Mitsubishi UFJ Trust & Banking
Japan
$2.83M – – –
UBS Group
36
UBS Group
Switzerland
$2.79M +$3.37M +343,430 +1,860%
Morgan Stanley
37
Morgan Stanley
New York
$2.57M +$561K +57,229 +21%
Barclays
38
Barclays
United Kingdom
$2.29M +$1.81M +184,366 +164%
First Trust Advisors
39
First Trust Advisors
Illinois
$1.86M +$1.1M +111,709 +86%
Citigroup
40
Citigroup
New York
$1.8M +$699K +71,267 +44%
AO
41
Allen Operations
New York
$1.68M – – –
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$1.58M +$8.46K +863 +0.4%
Mariner
43
Mariner
Kansas
$1.53M -$7.48K -763 -0.4%
Renaissance Technologies
44
Renaissance Technologies
New York
$1.5M +$1.75M +178,700 +1,176%
TRSOTSOK
45
Teachers Retirement System of the State of Kentucky
Kentucky
$1.34M +$98.1K +10,000 +6%
JP Morgan Chase
46
JP Morgan Chase
New York
$1.34M -$76.5K -7,802 -4%
Lazard Asset Management
47
Lazard Asset Management
New York
$1.26M -$1.38M -140,303 -46%
Schroder Investment Management Group
48
Schroder Investment Management Group
United Kingdom
$1.23M +$501K +51,119 +47%
CSS
49
Cubist Systematic Strategies
Connecticut
$1.23M +$473K +48,258 +43%
Balyasny Asset Management
50
Balyasny Asset Management
Illinois
$1.17M +$1.48M +151,339 New
1
2
3 4 5

RXRX Hedge Fund Activity: Q4 2022 in Review

144 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2022, worth a combined $953M — down 21% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RXRX positions and 19 closed out — a net gain of 1 holder — while 62 added to existing stakes and 30 trimmed.

The largest buyer was Kinnevik AB, opening a new position worth an estimated $75M. The largest seller was AllianceBernstein, cutting an estimated $27.9M.

  • 144 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2022, down from 146 in Q3 2022.
  • Funds reported $953M of Recursion Pharmaceuticals stock for Q4 2022, down 21% quarter-over-quarter.
  • 20 funds opened new Recursion Pharmaceuticals positions in Q4 2022 and 19 closed out, a net change of +1 holder.
  • The largest Recursion Pharmaceuticals buyer in Q4 2022 was Kinnevik AB, an estimated $75M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2022 was AllianceBernstein, an estimated $27.9M sold.

Based on aggregated 13F filings for Q4 2022.